AIDS Alert Archives – October 1, 2007
October 1, 2007
View Issues
-
AIDS vaccine efforts move forward, but full prevention is elusive goal
As HIV prevention strategies plod ahead and often falter, scientists and the international medical community continue to hold out hope that there will one day be a vaccine available to prevent HIV infection. -
New recommendations out on HIV & circumcision
Global policies are being updated with the recent issuance of recommendations from an expert consultation on male circumcision for HIV prevention. -
Researchers make strides in global battle against HIV
Good news on the research front: Results from a major study indicate that treating genital herpes may help keep the AIDS virus under control in women with both infections and may reduce the spread of HIV as well. -
Adherence Strategies: Study looks at adherence among alcohol abusers
HIV patients who abuse alcohol as their primary substance are less likely to adhere to their antiretroviral treatment regimen as their alcohol use increases, a recent study finds. -
Researchers note changing patterns of HIV morbidity
It's well known that HIV patients have been healthier and have lived longer since the advent of highly active antiretroviral therapy (HAART) in the mid-1990s. But as the population now ages and stays on these potent drugs for decades, there are many concerns about the impact of drug toxicity on long-term HIV patients. -
FDA Notifications
The FDA, on Aug. 13, 2007, granted tentative approval for a new fixed dose three-drug combination pill containing generic lamivudine, stavudine and nevirapine, to treat human immunodeficiency virus (HIV-1) infection in children outside the United States. -
AIDS Alert International: Vaccine study pipeline faces ethical and other challenges
HIV vaccine trials likely will continue for a decade or longer, raising questions about ethical considerations of enrolling participants across the globe. -
AIDS Alert International: Study finds excellent clinical ART responses from Kenyans
A new study found that 1,286 HIV patients in Kenya had excellent clinical and immunologic responses to antiretroviral therapy (ART), but they also switched regimens frequently.